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Background: Colorectal cancer remains one of the leading causes of death from cancer in industrialized countries.
Integrins are a family of heterodimeric glycoproteins involved in bidirectional cell signaling and participate in the
regulation of cell shape, adhesion, migration, differentiation, gene transcription, survival and proliferation. The α1
subunit is known to be involved in RAS/ERK proliferative pathway activation and plays an important role in
mammary carcinoma cell proliferation and migration. In the small intestine, α1 is present in the crypt proliferative
compartment and absent in the villus, but nothing is known about its expression in the colon mucosa, or in
colorectal cancer.
Results: In the present study, we demonstrated that in the colon mucosa, α1 is present in the basolateral domain
of the proliferative cells of the crypt, and in the surrounding myofibroblasts. We found higher levels of α1 mRNA in
86% of tumours compared to their corresponding matched margin tissues. Immunohistochemical analysis showed
that α1 staining was moderate to high in 65% of tumour cells and 97% of the reactive cells surrounding the
tumour cells vs 23% of normal epithelial cells.
Conclusion: Our findings suggest an active role for the α1β1 integrin in colorectal cancer progression.
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Colorectal cancer (CRC) is a major public health con-
cern in industrialized countries and remains one of the
leading causes of death from cancer. Its development
and progression are complex events involving many
factors leading to altered expression of genes and their
products. Integrins are a family of cell surface αβ
heterodimeric transmembrane receptors for extracellular
matrix components and cell-cell interactions. These re-
ceptors play a crucial role in mediating cell signaling in
response to the extracellular environment by participa-
ting in the regulation of cell shape, adhesion, migration,
differentiation, gene transcription, survival and prolifera-
tion [1-3]. In this context it is not surprising to have
identified integrin involvement in cancer progression.
Indeed, over-expression of the αvβ3, α5β1, αvβ5 and
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reproduction in any medium, provided the orwith the metastatic behaviour of breast, prostate and
lung cancers as well as melanomas are well docu-
mented [4]. Altered expression of integrins has also been
reported in CRC [5,6]. For example, the integrin α9β1
was detected in 50% of the tumours [7] while expression
of the pro-apoptotic α8β1 integrin was found to be
down-regulated in CRC and the pro-proliferative variant
form of the integrin α6β4 was exclusively found in CRC
cells [8,9].
Other integrins could also be involved in CRC. To
date, 18 α subunits and 8 β subunits are known to form
24 different non-covalently linked heterodimers [10]. In-
deed, nothing is known about integrin α1β1 expression
in CRC. The integrin α1 subunit is predominantly
present in stromal and smooth muscle cells and fibro-
blasts and is generally absent from normal epithelia
although it has been reported to be expressed in deve-
loping organs such as the kidney and skin [11]. In the
human intestine, the α1 subunit has been found to be
expressed in myofibroblasts and muscle cells as well as
in a subregion of the epithelial lining, being restricted to
the proliferative epithelial cell population located in theal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 (See legend on next page.)
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Figure 1 Representative immunohistochemical images showing expression of the α1 integrin subunit in CRC (B, D, F, H, L) and
corresponding matched resection margins (A, C, E, G, K). The α1 subunit was found to be expressed at higher levels in a significant number
of CRC tumours (D, F, H) compared to their corresponding matched normal tissues (C, E, G) where it was found to be predominantly expressed
in the proliferative cells of the crypt and below detection levels in normal surface epithelial cells (C, G). Note that the subepithelial myofibroblasts
were also stained for α1 in both normal tissues (A, E, G) and tumours (B, D, F, H). Scores: The margin in A and the tumour in B were both scored
0 (negative) whereas the tumour in D was scored 2 (strong) compared to score 0 (weak) for the matched margin C. The tumour in F was scored
1 (moderate) as was its corresponding margin in E (moderate). The margin in G was scored 0 and the matched tumour in H was scored 2. To
validate the specificity of the primary goat anti-α1 antibody, adjacent sections of the same normal (I, K) and cancer (J, L) specimens were stained
using 5 μg/ml of non-immune IgG (I, J) or anti-α1 IgG (K, L) as primary antibody. Scale bars = 50 μm.
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rent correlation between α1β1 expression and the proli-
ferative status of the cells appears to be consistent with
a pro-proliferative role for α1β1 signaling involving the
transmembrane caveolin-1, adaptor protein Shc and acti-
vation of the downstream RAS/ERK proliferative path-
way [11,14]. These observations suggest that integrin α1β1
may be involved in CRC. In this study, as a first step to test
this hypothesis, we investigated α1 integrin subunit expres-
sion in a set of colorectal adenocarcinoma specimens.
Results and discussion
In the digestive system, α1 integrin subunit expression
in epithelia has only been reported in the small intestine
and found to be confined to the lower crypts which con-
tain the progenitor cells [12,13]. The integrin α1 sub-
unit’s β partner, β1, has been observed throughout the
crypt-villus axis [12]. In the present study we confirmed
using two distinct antibodies that, as seen in the smallFigure 2 Representative indirect immunofluorescence images showin
subunit and laminin in a normal colon mucosa (A and B) and a mode
α1 subunit (red signal) was observed at the basolateral domain of normal e
panel B) compared to weak signal in the upper compartment (UC, panel A
epithelial cells (E) as well as in the adjacent subepithelial myofibroblasts (M
between the two tissues was stained with an anti-laminin antibody (greenintestine, the α1 subunit was confined to crypt cells and
was below the detection level in the differentiated epi-
thelial cells of both the upper gland and surface epithe-
lium of the normal colon (see * in Figure 1C, G and
Figure 2A). In the lower half of the glands α1 expression
was typically restricted to the basolateral domain of the
epithelial cells and was also strongly expressed in the
myofibroblasts [15] surrounding the crypts (Figure 1E,
G, K and Figure 2B). Expression of α1 in crypt cells
suggests a possible role in cell proliferation, as has been
reported in mouse breast cancer [16]. As in normal
epithelial cells, the α1 integrin subunit in cancers was
localized at the basolateral domain of the tumour cells
(Figure 1D, F, H). Indirect immunofluorescence on fro-
zen tissue sections clearly confirmed the presence of the
integrin α1 subunit in normal and tumour cells where
an anti-laminin, a specific basement membrane marker
[6], was used to delineate the epithelial staining from the
strong mesenchymal signal (Figure 2).g double-stained sections for the detection of the α1 integrin
rately differentiated colon adenocarcinoma specimen (C, D). The
pithelial cells of the lower crypt compartment (LC in panel A and E in
). In CRC, α1 was also localized at the basolateral domain of tumour
F) (Panels C, D). Basement membrane (arrows) located at the interface
staining). Nuclei were stained with DAPI (blue). Scale bar = 50 μm.
Figure 3 Expression of the α1 integrin subunit in CRC samples. (A) The α1 integrin subunit mRNA levels were evaluated by qPCR in 65 sets
of colorectal cancers and corresponding resection matched margins. Transcript levels for α1 were found to be increased in tumours relative to
their corresponding resection margins in 86% of samples (dotted line: cut off = 2). Expression of the α1 gene was calculated by the ΔΔCt method
and normalized to B2M expression. (p < 0.001, One-Sample T Test). (B) To illustrate the individual tendency of paired samples, transcript levels of
α1 were expressed as 1/ΔCt in each of the 65 matched margin and corresponding cancers showing the significant tendency for a higher level of
expression in cancers (p < 0.001, t-test two-tailed). (C) However, α1 subunit mRNA levels did not correlate with tumour stage (stage 1; 8 patients,
stage 2; 23 patients, stage 3; 26 patients and stage 4; 8 patients). (D) Integrin α1 expression at the protein level was analysed by
immunohistochemistry on a TMA containing 65 colorectal tissues and their corresponding resection margins only considering epithelial staining.
As illustrated in Figure 1, α1 immunostaining was scored as 0: negative or weak, 1: moderate or 2: strong staining. Results show that α1 staining
in carcinoma vs normal epithelial cells from the matched controls was significantly higher (McNemar-Bowker’s test, p < 0.001) in 37 specimens
(57%, gray area), similar in 25 specimens (38%) and lower in 3 specimens (5%). (E) The relative α1 integrin subunit expression was classified as
negative/weak or moderate/strong. The results show that only 23% of the normal tissues displayed moderate/strong epithelial staining for α1
compared to 65% of cancer cells and 97% of the peri-tumoral stromal cells. Bars represent 95% confidence level.
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script level revealed that the mRNA levels of the α1 integrin
subunit were significantly increased (from 2 up to 30 times)
in 86.2% of the 65 adenocarcinomas studied when com-
pared to their matched resection margins (Figure 3A and
B). Similar increases were seen in all four stages studied
(Figure 3C). However, based on the observations described
above, the observed increase in α1 mRNA levels included
both the tumoral and peri-tumoral tissues. Indeed, by im-
munohistochemistry, when considering relative protein
expression only in epithelial cells, 57.0% of the tumours
displayed higher expression of the α1 subunit than their
matched resection control tissues (Figure 3D). In fact, rela-
tive expression analysis showed that only 23% of the control
specimens displayed moderate/strong expression in the epi-
thelium compared to 65% of the tumour specimens and
97% of the peri-tumoral stromal tissue (Figure 3E).
These results emphasize that integrin α1 subunit ex-
pression is increased in a significant proportion of both
tumoral and peri-tumoral colonic tissues, a phenomenon
that appears to account for the strong expression of this
molecule at the transcript level. The fact that its ex-
pression is increased in 57% of the tumours relative to
their matched resection margins makes the integrin α1
subunit a marker of interest in the context where the ex-
pression of other integrin subunits were found to be al-
tered in comparable proportions such as α9 [7] and β4
[9]. Functionally, integrin α1β1 has been reported to par-
ticipate in cell invasion in the hepatocarcinoma model [17]
and to regulate invasion by enhancing proteinase expres-
sion in a mouse mammary carcinoma cell line [16]. In vitro
adhesion studies reported that integrin α1 blocking anti-
bodies reduced peritoneal gastric cell invasion [18] while in
the colorectal cancer HT-8/S11 cell line, α1, but not α2 or
β1 clustering induced the recruitment of the FAK/Src sig-
naling complex involved in cell invasion [19]. It has also
been reported that angiogenesis was reduced in integrin
α1-null mice [20]. Moreover, loss of the integrin α1 subunit
has been found to decrease the incidence and growth of
lung epithelial tumours initiated by oncogenic Kras [21]
consistent with the fact that Ras is a downstream effector
of the α1β1 integrin [14] and that oncogenic changes in the
Kras gene alone are not sufficient to confer a malignant
phenotype [22]. Kras mutation is well known in colorectal
cancer resistance to Cetuximab [23,24] but, to date, the link
with α1 in CRC is not known.
On the other hand, it has recently been reported that
cancer associated stromal cells have a pro-inflammatory
gene signature [25] and promote cancer cell invasiveness
[26,27]. Another study reported that fibroblasts could drive
tumour mammary carcinoma progression by modulating
biochemical forces through β1 integrin signalling [28]. The
data presented herein showing up-regulation of the in-
tegrin α1 subunit in the stromal compartment of colorectaltumours may also suggest a cooperative role of the integrin
α1β1 in colon cancer progression.
Conclusions
In conclusion, the data presented in this study identified
the expression and predominant localization of the α1
integrin subunit in the proliferative compartment of the
normal colonic epithelium and demonstrated that α1 ex-
pression was significantly up-regulated in CRC in both
tumour cells and surrounding stromal cells, suggesting a
positive role for the α1β1 integrin in CRC progression.
Methods
Patients, tumour tissues and tissue microarrays
Primary colorectal adenocarcinomas and paired margin
tissues were obtained from 65 patients undergoing surgi-
cal resection without prior neoadjuvant therapy. Tissues
were obtained after patient’s written informed consent,
according to a protocol approved by the Institutional
Human Subject Review Board of the Centre Hospitalier
Universitaire de Sherbrooke. Staging of the adenocarcin-
omas was according to the TNM classification of tumours.
There were 8 stage 1, 23 stage 2, 26 stage 3 and 8 stage 4
specimens. For immunohistochemistry, samples were
fixed with 4% paraformaldehyde in 0.1 M PBS at 4°C over-
night, dehydrated in graded alcohols, and then embed-
ded in paraffin. For cryosections, tissues were embedded
as previously described [9,12]. Total RNA was extrac-
ted from tissues using the Totally RNA kit (Invitrogen,
Burlington, ON) and processed according to the manufac-
turer’s instructions [8,9].
Tissue microarrays (TMA) were performed as previously
described [29]. Briefly, 5μm thick serial sections were
processed for routine hematoxylin and eosin staining, in
order to hallmark the tissue region for TMA. Tissue cores
with a diameter of 2 mm were removed from fixed paraf-
fin–embedded tissue blocks using a 2 mm dermatological
biopsy punch (Miltex Inc. York, PA) and arrayed in a paraf-
fin mold which was first covered with double-sided adhe-
sive to hold the cores in the correct position. Once all cores
were deposited at the bottom of the mold, hot paraffin was
poured to fill the mold and create a new block after incuba-
tion for one hour at 4°C. From the new block, sections of
5μm in thickness were made. Each section was spread on a
glass slide and stored at room temperature.
Immunohistochemistry and expression analysis
Sections (5 μm thick) cut from paraffin-embedded TMA
were mounted on charged slides, deparaffinated in xylene
and rehydrated in graded alcohol. Antigen retrieval was
performed in 0.01M citrate buffer, pH 6, in a micro-
wave pressure cooker for 30 minutes. Slides were cooled
to room temperature before reacting with a peroxi-
dase blocking reagent (0.3% H2O2) for 30 minutes, a
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Inc, Burlington, ON) for 15 min, and blocking serum [PBS
1×, 0.1% BSA (Sigma-Aldrich, Oakville, ON), 0.2% Triton
X-100 (ICN Biochemicals, Aurora, OH), 0.1% donkey
serum, 0.1% goat serum] for 30 minutes. Sections were in-
cubated overnight at 4°C with anti-human integrin α1
purified polyclonal sheep IgG (5 μg/ml, AF5676, R & D
Systems, Minneapolis, MN) or with equal amounts of
sheep non-immune IgG (sc-2717, Santa Cruz Biotechnol-
ogy, Santa Cruz, CA) as negative control, followed by incu-
bation with an anti-sheep biotinylated secondary antibody
(Vector Laboratories) for one hour at room temperature.
Then, tissues were incubated with a streptavidin HRP con-
jugated solution (1:1000, Millipore, Billerica, MA) for one
hour and the colour developed with 3,30- diaminobenzidine
(Vector Laboratories) in a buffered substrate solution.
Slides were counterstained with light hematoxylin, dehy-
drated and cover-slipped. Representative images were
acquired using a Leika DM-RXA microscope. Protein ex-
pression in different cell types, including epithelial tumour
cells, epithelial normal cells and reactive cells, was sepa-
rated into 2 groups based on staining intensity: negative/
low or moderate/strong expression. Expression in tumour
cells was compared to the normal epithelial cells of the
respective margin and scored as 0; no or weak staining, 1;
moderate, and 2; strong staining.
Indirect immunofluorescence
To determine the α1 expression pattern, 3 μm thick sec-
tions were cut from different normal colonic mucosa
and adenocarcinomas samples. First, sections were fixed
10 min in ethanol at -20°C and then washed 3 times
with chilled PBS. Then, nonspecific protein-protein in-
teractions were blocked for 30 minutes with 10% blotto
followed by 2 hours incubation with the primary α1
mouse monoclonal antibodies TS27 (Endogen, Woburn,
MA) diluted 1:10, and an anti-laminin rabbit antibody
(Serotec, Raleigh, NC) diluted 1:1000 in 10% blotto.
After three washes with ice-cold PBS, slides were incu-
bated one hour at room temperature with AlexaFluor
488 and AlexaFluor 594 conjugated secondary antibodies
directed against mouse and rabbit IgG (Molecular Probe,
Burlington, ON). Slides were then stained with DAPI (40,6-
diamidino-2-phenylindole, 2%) and then mounted in gly-
cerol: PBS (9:1) containing 0.1% paraphenylenediamine and
observed with a Leica DM-RXA microscope. Images were
acquired and composites generated with the MetaMorph
Imaging System (Universal Imaging, West Chester, PA).
Real time quantitative RT-PCR
The RNA was reverse-transcribed to cDNA with AMV
reverse transcriptase (Roche, Laval, QC) following the
manufacturer’s instructions. Primers used to amplify α1
were 50-CATCAGGTGGGGATGGTAAG-30 and 50-TGGCTCAAAATTCATGGTCA-30. B2M was used as house-
keeping gene and primers were 50-GTGCTCGCGC
TACTCTCTC-30 and 50-GTCAACTTCAATGTCGGAT-
30. Quantitative PCR was performed using a MX3000P
Real-Time System (Stratagene, Cedar Creek, TX). α1
gene expression was calculated by the ΔΔCT method
and normalized to B2M expression [30].
Statistical analysis
The One-Sample Student’s t-test was used to determine the
statistical significance of mRNA expression analyses. For
immunohistological analyses, the McNemar-Bowker’s test
was used to compare scores between tumours and non-
malignant samples.
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